The vastly neglected biomarkers contributing to early clinical development failure

American Pharmaceutical Review

Volumn 11, Issue 3, 2008, Pages

  Feuerstein, Giora ^a   Gill, Davinder ^a   Dormer, Charles ^a   Ruffolo, Robert R ^a   Rutkowski, J Lynn ^a   Walsh, Frank S ^a   Hurko, Orest ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTIDEPRESSANT AGENT; APREPITANT; BIOLOGICAL MARKER; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GLUTAMATE TRANSPORTER; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PERTUZUMAB; RADIOLIGAND; SEROTONIN 1A RECEPTOR; SEROTONIN 2 ANTAGONIST; TIROFIBAN; TRACER; TRASTUZUMAB;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PENETRATION; DRUG RESEARCH; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 55849098556     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Franz, S. Pharma faces major challenges after a year of failures and heated battles Nature reviews Drug Discovery 6:5-7, 2007.
2. Feuerstein GZ, Dormer C, Ruffolo RR Jr, Stiles G, Walsh FS, Rutkowski JL. Translational Medicine Perspectives of Biomarkers in Drug Discovery and Development: Part I Target Selection and Validation - Biomarkers Take Center Stage. Am Drug Discovery 2 vol 5: 36-43, 2007.
3. Scham, A.J. et al. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab. Rev. 29, 923-956, 1997.
4. Meyer JH, Ichise M. Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. J Neuroimaging. 11:30-39, 2001.
5. Bergstrom. et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012, 2004.
6. Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 28:595-608, 2001.
7. Alvete JJ. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proc Soc Exp Biol Med. 208:346-360, 1995.
8. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284:1549-1558, 2000.
9. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 16:103:201-206, 2001.
10. Sizing ID, Bailly V, McCoon P, Chang W, Rao S, Pablo L, Rennard R, Walsh M, Li Z, Zafari M, Dobles M, Tarilonte L, Miklasz S, Majeau G, Godbout K, Scott ML, Rennert PD.Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J Immunology 178:2249-2261, 2007.
11. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311:1924-1927, 2006.
12. Schaefer NG, Pestalozzi BC, Knuth A, Renner C. Potential use of Humanized antibodies in the treatment of breast cancer. Expert Rev Anticancer Ther. 6:1065-1074, 2006.
13. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M.Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 13:3483-3492,2006.
14. Tracey D , Klareskog L, Sasso EH , Salfeld JG , Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics xx, 2007.
15. Ulfgren, A. K., Lindblad, S., Klareskog, L., Andersson, J, Andersson, U. (1995). Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 54, 654?661, 1995.
16. Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163, 1521 1528, 1999.
17. Barrera P, Joosten L A, den Broeder A A, van de Putte L B, van Riel P L, van den Berg W B.